PE20040669A1 - Derivados de fenilalanina enamida - Google Patents

Derivados de fenilalanina enamida

Info

Publication number
PE20040669A1
PE20040669A1 PE2003000713A PE2003000713A PE20040669A1 PE 20040669 A1 PE20040669 A1 PE 20040669A1 PE 2003000713 A PE2003000713 A PE 2003000713A PE 2003000713 A PE2003000713 A PE 2003000713A PE 20040669 A1 PE20040669 A1 PE 20040669A1
Authority
PE
Peru
Prior art keywords
dichloroisonicotinoil
ilamino
propanoate
spiro
bromo
Prior art date
Application number
PE2003000713A
Other languages
English (en)
Inventor
Stuart Bailey
Julien Alistair Brown
Stephen Brand
Original Assignee
Celltech Randd Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Randd Ltd filed Critical Celltech Randd Ltd
Publication of PE20040669A1 publication Critical patent/PE20040669A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, SUS SALES, SOLVATOS Y N-OXIDOS DONDE R1 ES -CH3, -(CH2)3CH3, -CH2CH2OH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: BUTIL (2S)-2-(2-BROMO-3-OXO-ESPIRO[3.5]NON-1-EN-1-ILAMINO)-3-{4-[(3,5-DICLOROISONICOTINOIL)AMINO]FENIL}PROPANOATO; 2-HIDROXIETIL (2S)-2-(2-BROMO-3-OXO-SPIRO[3.5]NON-1-EN-1-ILAMINO)-3-{4-[(3,5-DICLOROISONICOTINOIL)AMINO]FENIL}PROPANOATO Y METIL (2S)-2-(2-BROMO-3-OXO-SPIRO[3.5]NON-1-EN-1-ILAMINO)-3-{4-[(3,5-DICLOROISONICOTINOIL)AMINO]FENIL}PROPANOATO; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHOS COMPUESTOS QUE SON INHIBIDORES DE a4-INTEGRINAS UTILES EN EL TRATAMIENTO Y PROFILAXIS DE ENFERMEDADES QUE INCLUYEN INFLAMACIONES
PE2003000713A 2002-07-17 2003-07-16 Derivados de fenilalanina enamida PE20040669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0216568.6A GB0216568D0 (en) 2002-07-17 2002-07-17 Chemical compounds

Publications (1)

Publication Number Publication Date
PE20040669A1 true PE20040669A1 (es) 2004-09-25

Family

ID=9940610

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000713A PE20040669A1 (es) 2002-07-17 2003-07-16 Derivados de fenilalanina enamida

Country Status (10)

Country Link
US (1) US6872719B1 (es)
EP (1) EP1524980A1 (es)
JP (1) JP2005536504A (es)
AR (1) AR040579A1 (es)
AU (1) AU2003281162A1 (es)
CA (1) CA2492381A1 (es)
GB (1) GB0216568D0 (es)
PE (1) PE20040669A1 (es)
TW (1) TW200404782A (es)
WO (1) WO2004006918A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1370531T1 (sl) * 2001-02-22 2007-08-31 Ucb Pharma Sa Derivati fenilalanin enamida s ciklobutensko skupino, za uporabo kot integrin inhibitorji
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
WO2008138591A2 (en) * 2007-05-14 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives,processes for preparing them and their uses
WO2008138615A1 (en) * 2007-05-16 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
KR20110008086A (ko) 2008-04-11 2011-01-25 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
CN102282168A (zh) * 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US20150105278A1 (en) 2011-10-17 2015-04-16 Westfaelische Wilhelms-Universitaet Muenster Methods or risk assessment of pml and related apparatus
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4ベータ7インテグリンの阻害のための化合物
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
CA3116769C (en) 2018-10-30 2023-08-22 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60130910T2 (de) * 2000-04-17 2008-07-10 Ucb Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
SI1370531T1 (sl) * 2001-02-22 2007-08-31 Ucb Pharma Sa Derivati fenilalanin enamida s ciklobutensko skupino, za uporabo kot integrin inhibitorji

Also Published As

Publication number Publication date
JP2005536504A (ja) 2005-12-02
WO2004006918A1 (en) 2004-01-22
EP1524980A1 (en) 2005-04-27
US6872719B1 (en) 2005-03-29
TW200404782A (en) 2004-04-01
AU2003281162A1 (en) 2004-02-02
GB0216568D0 (en) 2002-08-28
AR040579A1 (es) 2005-04-13
CA2492381A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
PE20040669A1 (es) Derivados de fenilalanina enamida
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
FI956119A (fi) Fenyyliheterosyklejä syklo-oksigenaasi-2-inhibiittoreina
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
WO2003077855A3 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
PE20010634A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
EE200100487A (et) Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
PE20050349A1 (es) Compuestos de aril o heteroaril amida
SE0202463D0 (sv) Novel compounds
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
DK1663206T3 (da) 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist
DK1569899T3 (da) Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
ATE374765T1 (de) Substituierte heterocyclische amide
CL2004000382A1 (es) Tetrahidroisoquinolinas sustituidas, proceso de preparacion, y composicion farmaceutica, utiles en el tratamiento y prevencion de estados patologicos que se alivian con un agonista de 5-ht6.
PE20061155A1 (es) Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
MXPA04009476A (es) Compuestos de (tiazol-4,2-disustituidos-5-il)amina como inhibidores de la pde7.
EA200400994A1 (ru) Новые 1,2,3-замещенные производные индолизина, являющиеся ингибиторами факторов роста фибробластов, способ их получения и фармацевтические композиции, содержащие их
AR041340A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
AR044175A1 (es) Compuestos de cefemo
PA8579301A1 (es) Derivados de tiazol
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.
CY1108238T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της

Legal Events

Date Code Title Description
FC Refusal